Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased By 5.09%

September 17, 2017 - By Marie Mckinney

 Casi Pharmaceuticals Incorporated (NASDAQ:CASI) Shorted Shares Increased By 5.09%

Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.25, from 1.13 in 2016Q3. It turned negative, as 3 investors sold CASI Pharmaceuticals Inc shares while 5 reduced holdings. 1 funds opened positions while 6 raised stakes. 2.22 million shares or 0.50% more from 2.21 million shares in 2016Q3 were reported.
Blackrock Investment Mgmt Ltd Liability Company owns 3,375 shares for 0% of their portfolio. Next Gp, a Texas-based fund reported 2 shares. Renaissance Technology Lc reported 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). Geode Capital Management Limited Co reported 38,700 shares or 0% of all its holdings. California Employees Retirement Sys has invested 0% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI). Deutsche Natl Bank Ag owns 32,901 shares. Fincl Bank Of America De has invested 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). Blackrock Fund Advsrs holds 0% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI) for 37,886 shares. Vanguard Group Incorporated Inc holds 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI) or 346,177 shares. Creative Planning reported 9 shares. Williams Jones & Assocs Limited Liability Company holds 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI) or 17,812 shares. The New York-based Morgan Stanley has invested 0% in CASI Pharmaceuticals Inc (NASDAQ:CASI). Wellington Shields Cap Limited Liability Co holds 528,447 shares or 0.1% of its portfolio. Blackrock Institutional Trust Company Na invested 0% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI). Penobscot Investment Mngmt holds 0.01% of its portfolio in CASI Pharmaceuticals Inc (NASDAQ:CASI) for 27,000 shares.

The stock of Casi Pharmaceuticals Incorporated (NASDAQ:CASI) registered an increase of 5.09% in short interest. CASI’s total short interest was 74,300 shares in September as published by FINRA. Its up 5.09% from 70,700 shares, reported previously. With 9,200 shares average volume, it will take short sellers 8 days to cover their CASI’s short positions. The short interest to Casi Pharmaceuticals Incorporated’s float is 0.2%.

The stock increased 15.38% or $0.2 on September 15, reaching $1.5. About 355,943 shares traded or 704.23% up from the average. CASI Pharmaceuticals Inc (NASDAQ:CASI) has declined 17.65% since September 17, 2016 and is downtrending. It has underperformed by 34.35% the S&P500.

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $90.29 million. The Firm is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It currently has negative earnings. It operates through the development of targeted therapeutics for the treatment of cancer segment.

CASI Pharmaceuticals Inc (NASDAQ:CASI) Ratings Coverage

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, October 29 by H.C. Wainwright. Maxim Group initiated the shares of CASI in report on Thursday, September 22 with “Buy” rating. As per Monday, August 14, the company rating was maintained by Maxim Group.

More notable recent CASI Pharmaceuticals Inc (NASDAQ:CASI) news were published by: Prnewswire.com which released: “CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In …” on August 16, 2016, also Prnewswire.com with their article: “CASI Pharmaceuticals Reports 2015 Fourth Quarter And Full Year Financial Results” published on March 28, 2016, Thestreet.com published: “CASI Pharmaceuticals (CASI) Stock Spikes on EU Orphan Drug Designation” on October 14, 2015. More interesting news about CASI Pharmaceuticals Inc (NASDAQ:CASI) were released by: Prnewswire.com and their article: “CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global …” published on September 06, 2017 as well as Prnewswire.com‘s news article titled: “James E. Goldschmidt, Ph.D. Joins CASI Pharmaceuticals As Vice President Of …” with publication date: April 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.